Drug Profile
Labetuzumab anti-DTPA-indium bispecific monoclonal antibody
Latest Information Update: 27 Oct 2020
Price :
$50
*
At a glance
- Originator IBC Pharmaceuticals; Immunomedics
- Developer Immunomedics
- Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Recombinant fusion proteins
- Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Diagnosis) in France (IV)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV)